Major findings and recent advances in virus–like particle (VLP)-based vaccines

MO Mohsen, L Zha, G Cabral-Miranda… - Seminars in …, 2017 - Elsevier
Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last
three decades. VLPs constitute versatile tools in vaccine development due to their …

Sex and gender differences in the outcomes of vaccination over the life course

KL Flanagan, AL Fink, M Plebanski… - Annual review of cell …, 2017 - annualreviews.org
Both sex (ie, biological differences) and gender (ie, social or cultural influences) impact
vaccine acceptance, responses, and outcomes. Clinical data illustrate that among children …

Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised …

S Rts - Lancet, 2015 - thelancet.com
Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Vaccines for the 21st century

I Delany, R Rappuoli, E De Gregorio - EMBO molecular medicine, 2014 - embopress.org
In the last century, vaccination has been the most effective medical intervention to reduce
death and morbidity caused by infectious diseases. It is believed that vaccines save at least …

A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver

LT Wang, LS Pereira, Y Flores-Garcia, J O'Connor… - Immunity, 2020 - cell.com
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised …

MT White, R Verity, JT Griffin, KP Asante… - The Lancet infectious …, 2015 - thelancet.com
Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …

malERA: an updated research agenda for malaria elimination and eradication

RN Rabinovich, C Drakeley, AA Djimde, BF Hall… - PLoS …, 2017 - journals.plos.org
Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes

GE Weiss, PR Gilson, T Taechalertpaisarn… - PLoS …, 2015 - journals.plos.org
During blood stage Plasmodium falciparum infection, merozoites invade uninfected
erythrocytes via a complex, multistep process involving a series of distinct receptor-ligand …

Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 …

RTS, S Clinical Trials Partnership (2014) - PLoS medicine, 2014 - journals.plos.org
Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Malaria vaccines: progress to date

DI Stanisic, MF Good - BioDrugs, 2023 - Springer
Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …